{"nctId":"NCT01154036","briefTitle":"MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)","startDateStruct":{"date":"2010-07"},"conditions":["Hypercholesterolemia"],"count":1547,"armGroups":[{"label":"Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe 10 mg","Drug: atorvastatin"]},{"label":"Phase I: Atorvastatin 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: atorvastatin"]},{"label":"Phase I: Rosuvastatin 10 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: rosuvastatin"]},{"label":"Phase II: EZ 10mg+Atorva 10mg","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe 10 mg","Drug: atorvastatin"]},{"label":"Phase II: EZ 10mg + Atorva 20mg [A]","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe 10 mg","Drug: atorvastatin"]},{"label":"Phase II: Atorva 40mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: atorvastatin"]},{"label":"Phase II: EZ 10mg + Atorva 20mg [R]","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe 10 mg","Drug: atorvastatin"]},{"label":"Phase II: Rosuvastatin 20mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: rosuvastatin"]}],"interventions":[{"name":"ezetimibe 10 mg","otherNames":[]},{"name":"atorvastatin","otherNames":[]},{"name":"Comparator: rosuvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient is at high cardiovascular risk and meets one of the following conditions: has never taken lipid-lowering therapy or has been off such therapy for at least 6 weeks; or, is currently taking a stable dose of certain lipid-lowering agents\n* Patient is willing to maintain a cholesterol lowering diet during the study\n* Female patients receiving non-cyclical hormone therapy have maintained a stable dose and regimen for at least 8 weeks and are willing to continue the same regimen during the study\n\nExclusion Criteria:\n\n* Patient is Asian\n* Patient routinely has more than 2 alcoholic drinks per day\n* Female patient is pregnant or breastfeeding\n* Patient has congestive heart failure\n* Patient has had a myocardial infarction, coronary bypass surgery, angioplasty, or acute coronary syndrome within 3 months of screening\n* Patient has uncontrolled cardiac arrhythmias\n* Patient has had a partial ileal or gastric bypass or other significant intestinal malabsorption\n* Patient has uncontrolled high blood pressure\n* Patient has kidney disease\n* Patient has any disease known to influence blood lipid levels\n* Patient has any disorders of the blood, digestive system, or nervous system including stroke and degenerative disease that would limit study participation\n* Patient has poorly controlled or newly diagnosed diabetes\n* Patient is known to be HIV positive\n* Patient has a history of cancer in the last 5 years, except certain skin and cervical cancers","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)","description":"LDL-C levels measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. LDL-C was calculated using the Friedewald method when triglyceride (TG)\\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG≥350 mg/dL (3.95 mmol/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.8","spread":"23.6"},{"groupId":"OG001","value":"-10.1","spread":"20.8"},{"groupId":"OG002","value":"-13.8","spread":"22.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).","description":"LDL-C levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12). Baseline was defined as the average of the values at Visits 5 and 6. LDL-C was calculated using the Friedewald method when triglyceride (TG)\\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG ≥350 mg/dL (3.95 mmol/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.4","spread":"31.1"},{"groupId":"OG001","value":"-8.1","spread":"23.3"},{"groupId":"OG002","value":"-19.3","spread":"32.1"},{"groupId":"OG003","value":"-8.4","spread":"20.8"},{"groupId":"OG004","value":"2.4","spread":"27.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":"4.55"},{"groupId":"OG001","value":"37.4","spread":"2.23"},{"groupId":"OG002","value":"43.6","spread":"1.64"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":"4.53"},{"groupId":"OG001","value":"34.1","spread":"4.28"},{"groupId":"OG002","value":"53.5","spread":"3.30"},{"groupId":"OG003","value":"35.8","spread":"3.38"},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":"3.62"},{"groupId":"OG001","value":"3.0","spread":"0.78"},{"groupId":"OG002","value":"6.6","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"3.53"},{"groupId":"OG001","value":"0.8","spread":"0.81"},{"groupId":"OG002","value":"15.4","spread":"2.39"},{"groupId":"OG003","value":"3.0","spread":"1.20"},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (TC) (Phase I)","description":"TC measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":"17.0"},{"groupId":"OG001","value":"-6.3","spread":"14.1"},{"groupId":"OG002","value":"-8.2","spread":"14.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (TC) (Phase II)","description":"TC levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.2","spread":"19.9"},{"groupId":"OG001","value":"-2.9","spread":"15.7"},{"groupId":"OG002","value":"-13.1","spread":"22.8"},{"groupId":"OG003","value":"-5.0","spread":"14.0"},{"groupId":"OG004","value":"2.2","spread":"15.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides (TG) (Phase I)","description":"TG measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":null},{"groupId":"OG001","value":"-3.9","spread":null},{"groupId":"OG002","value":"-1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides (TG) (Phase II)","description":"TG levels measured at Baseline (Week 6: end of Phase I) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":null},{"groupId":"OG001","value":"-3.1","spread":null},{"groupId":"OG002","value":"-10.2","spread":null},{"groupId":"OG003","value":"-3.2","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)","description":"HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"11.9"},{"groupId":"OG001","value":"-1.3","spread":"11.6"},{"groupId":"OG002","value":"1.0","spread":"13.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C (Phase II)","description":"HDL-C levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"14.1"},{"groupId":"OG001","value":"1.0","spread":"16.0"},{"groupId":"OG002","value":"-0.8","spread":"13.7"},{"groupId":"OG003","value":"0.0","spread":"15.2"},{"groupId":"OG004","value":"0.0","spread":"11.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)","description":"Apo-B measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.1","spread":"20.7"},{"groupId":"OG001","value":"-6.1","spread":"20.7"},{"groupId":"OG002","value":"-7.6","spread":"20.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B (Phase II)","description":"Apo-B levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.0","spread":"26.5"},{"groupId":"OG001","value":"-6.3","spread":"19.6"},{"groupId":"OG002","value":"-14.0","spread":"25.1"},{"groupId":"OG003","value":"-4.9","spread":"21.8"},{"groupId":"OG004","value":"-4.0","spread":"16.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)","description":"Apo-A-I measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"13.1"},{"groupId":"OG001","value":"-1.9","spread":"12.5"},{"groupId":"OG002","value":"1.4","spread":"13.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A-I (Phase II)","description":"Apo-A-I levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"11.9"},{"groupId":"OG001","value":"1.4","spread":"14.1"},{"groupId":"OG002","value":"-0.6","spread":"14.4"},{"groupId":"OG003","value":"0.0","spread":"16.0"},{"groupId":"OG004","value":"-0.7","spread":"14.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C (Phase I)","description":"Non-HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.0","spread":"22.3"},{"groupId":"OG001","value":"-7.9","spread":"17.6"},{"groupId":"OG002","value":"-11.1","spread":"19.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C (Phase II)","description":"Non-HDL-C levels calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.5","spread":"26.1"},{"groupId":"OG001","value":"-5.5","spread":"16.6"},{"groupId":"OG002","value":"-18.1","spread":"29.4"},{"groupId":"OG003","value":"-6.3","spread":"18.5"},{"groupId":"OG004","value":"-0.5","spread":"17.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in TC/HDL-C Ratio (Phase I)","description":"TC/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":"17.9"},{"groupId":"OG001","value":"-4.5","spread":"16.8"},{"groupId":"OG002","value":"-9.0","spread":"19.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in TC/HDL-C Ratio (Phase II)","description":"TC/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"21.7"},{"groupId":"OG001","value":"-6.5","spread":"13.9"},{"groupId":"OG002","value":"-11.7","spread":"23.3"},{"groupId":"OG003","value":"-4.0","spread":"17.8"},{"groupId":"OG004","value":"-1.0","spread":"9.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)","description":"LDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.9","spread":"23.6"},{"groupId":"OG001","value":"-7.1","spread":"23.2"},{"groupId":"OG002","value":"-14.7","spread":"26.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)","description":"LDL-C/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.6","spread":"31.4"},{"groupId":"OG001","value":"-8.2","spread":"20.6"},{"groupId":"OG002","value":"-18.2","spread":"31.6"},{"groupId":"OG003","value":"-7.5","spread":"21.5"},{"groupId":"OG004","value":"-4.5","spread":"22.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)","description":"Apo B/Apo A-I ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","spread":"22.3"},{"groupId":"OG001","value":"-4.8","spread":"18.9"},{"groupId":"OG002","value":"-8.8","spread":"23.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)","description":"Apo B/Apo A-I Ratio calculated at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.2","spread":"26.2"},{"groupId":"OG001","value":"-6.4","spread":"19.4"},{"groupId":"OG002","value":"-11.2","spread":"27.5"},{"groupId":"OG003","value":"-5.4","spread":"21.5"},{"groupId":"OG004","value":"-6.7","spread":"11.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)","description":"Non HDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.9","spread":"23.9"},{"groupId":"OG001","value":"-6.3","spread":"22.8"},{"groupId":"OG002","value":"-12.2","spread":"25.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)","description":"Non HDL-C/HDL-C Ratio calculated at baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.2","spread":"29.5"},{"groupId":"OG001","value":"-8.8","spread":"18.8"},{"groupId":"OG002","value":"-16.3","spread":"32.3"},{"groupId":"OG003","value":"-5.9","spread":"23.4"},{"groupId":"OG004","value":"-1.9","spread":"12.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)","description":"hs-CRP measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.5","spread":null},{"groupId":"OG001","value":"-6.6","spread":null},{"groupId":"OG002","value":"-9.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Hs-CRP (Phase II)","description":"hs-CRP measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.5","spread":null},{"groupId":"OG001","value":"-6.4","spread":null},{"groupId":"OG002","value":"-10.9","spread":null},{"groupId":"OG003","value":"0.7","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":120},"commonTop":[]}}}